Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers October 19, 2017
Pharmacy Choice - News - Pharmaceutical Industry Trends and Policy - October 19, 2017

Pharmacy News

 Pharmaceutical Industry Trends and Policy
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

10/12/17 - LUPIN ACQUIRES US FIRM SYMBIOMIX FOR $150 MILLION
Pharmaceutical company Lupin has acquired Symbiomix Therapeutics LLC of the US for $150 million, including $50 million as upfront and other time-based payments. There would be other sales-based contingent payments. Lupin previously entered into an option to acquire privately-held Symbiomix, which offers innovative therapies for gynaecological...
10/11/17 - "Examining How Covered Entities Utilize the 340B Drug Pricing Program."
Chairman Murphy, Ranking Member DeGette and Members of the Subcommittee, my name is Charlie Reuland and I am the executive vice president and chief operating officer of The Johns Hopkins Hospital. I. The Johns Hopkins Hospital in Baltimore City, History and Demographics. The bequest left by the philanthropist Johns Hopkins, whose gifts established
10/11/17 - A Deep Dive Into MannKind's Big Bet On Afrezza
It's been a long road for MannKind Corporation and its Afrezza inhalable insulin product. Here's a look at inhalable insulin's long journey and what the new FDA ruling means for MannKind. At the time, MannKind was already working on Afrezza and submitted an NDA to the FDA on March 16, 2009.
10/11/17 - AbbVie (ABBV), Turnstone Biologics Announce Pact on Viral Immunotherapies in Oncology [Sport360]
AbbVie, a global biopharmaceutical company, and Turnstone Biologics, a clinical-stage immuno-oncology company, today announced a research, option and license agreement whereby AbbVie obtained an exclusive option to license up to three of Turnstone`s next-generation oncolytic viral immunotherapies. This unique approach to cancer treatment...
10/11/17 - Abeona Therapeutics Enrolls First Two Patients in Pivotal Expansion of Phase 1/2 Clinical Trial in MPS IIIA
ABO-102 Patients Enrolled in Cohort 3 at 3 E13 vg/kg Accelerated enrollments begin with first Patient Enrolled at clinical site in Australia; Patient Screening at Spain site underway Day 30 results demonstrate 67% Heparan sulfate reduction in the CNS and 92% reduction in urinary heparan sulfate and normalization of 76% points in liver volume NEW YO
10/11/17 - Absorption Systems Announces Major Expansion of Facilities
By a News Reporter-Staff News Editor at Biotech Week Absorption Systems, a global leader in the advancement of translational medicine, announces a major expansion of two research facilities; near Philadelphia, PA and San Diego, CA. The expansion is driven by sustained demand for the company's high quality contract services to pharmaceutical and..
10/11/17 - Accelerated Path to FDA Approval Subject of Upcoming Panel at CCIT
An alternate path to Food and Drug Administration approval that is gaining popularity will be the focus of a panel discussion on Wednesday, October 18 at the New Jersey Economic Development Authority's Commercialization Center for Innovative Technologies in North Brunswick. Known as the 505 new drug application, this approach to pursuing FDA approv
10/11/17 - Acquisition Of Zevacor Pharma Complete, Rebranding As SOFIE
By a News Reporter-Staff News Editor at Technology News Focus Sofie Biosciences, Inc., the molecular imaging company specializing in novel tools for PET imaging and radiosynthesis of PET compounds, has announced the completion of the acquisition of Zevacor Pharma to form " SOFIE". The addition of Zevacor Pharma's 16 radiopharmacies and Contract..
10/11/17 - Acura Pharmaceuticals Advances LTX - 03 and its LIMITx Technology
Release date- 10102017- PALATINE, Ill.- Acura Pharmaceuticals, Inc., a specialty pharmaceutical company innovating abuse deterrent drugs, today announced that topline results from clinical study AP-LTX-300 for its LIMITx oral abuse deterrent drug LTX-03 demonstrated rapid release of drug from the micro-particle formulation providing expected...
10/11/17 - Aerie Pharmaceuticals Announces Appointment of New Members of its Research and Development Team
Release date- 10102017- IRVINE, Calif.- Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first in class therapies for the treatment of glaucoma and other diseases of the eye, today announced the appointment of 11 employees to its Research and Development team located
10/11/17 - After 'Brazen' Drug Company Move, McCaskill Takes Action to Protect Consumers With Bill Aimed at Ending Such Deals
Claire McCaskill, D- Mo., issued the following news release:. In a recent deal, Allergan transferred patents on Restasis, a blockbuster eye medicine, to the Saint Regis Mohawk Tribe, which has now used tribal sovereignty to argue that the patents should not be subject to challenge at the U.S. Patent and Trademark Office. Earlier this week McCaskill
10/11/17 - Akari Therapeutics Announces Further Clinical Progress
Akari Therapeutics, Plc, a biopharmaceutical company focused on developing inhibitors of acute and chronic inflammation, specifically the complement system, the eicosanoid system and the bioamine system for the treatment of rare and orphan diseases, announces that three additional patients have been enrolled in the ongoing Phase II COBALT clinica
10/11/17 - Akcea Therapeutics Volanesorsen Receives Promising Innovative Medicine (PIM) Status for the Treatment of Familial Chylomicronaemia Syndrome (FCS) [Syrian Arab News Agency]
Akcea Therapeutics UK, the UK subsidiary of Akcea Therapeutics Inc., an affiliate of Ionis Pharmaceuticals, Inc., is focused on developing and commercialising drugs to treat patients with serious cardiometabolic lipid disorders. This designation demonstrates the potential to address clear unmet medical needs in the treatment of this debilitating...
10/11/17 - Allergan to Present Data From More Than 20 Abstracts at the 2017 Fall Clinical Dermatology Conference
Allergan, a leading global pharmaceutical company, announced today that it will present 22 abstracts at the 2017 Fall Clinical Dermatology Conference in Las Vegas from October 12-15. Among the highlights are new presentations on acne and ongoing redness associated with rosacea, containing efficacy data on ACZONE Gel, 7.5% and RHOFADE CREAM,
10/11/17 - Allergan to Present New Dry Eye Data at the American Academy of Optometry Meeting in Chicago
Release date- 10102017- DUBLIN.- Allergan plc, a leading global pharmaceutical company, today announced several Allergan-supported abstracts were selected for poster presentation at the Annual American Academy of Optometry in Chicago, Illinois from October 11- 14, 2017. Date and Time: Friday, October 13 10:00 am- 12:00 pm CT. Authors: D. Evans, S.
10/11/17 - Amgen And Simcere Announce Strategic Collaboration To Co-Develop And Commercialize Biosimilars In China
By a News Reporter-Staff News Editor at Biotech Week Amgen and Simcere Pharmaceutical Group announced the execution of an exclusive agreement to co-develop and commercialize four biosimilars in China. Simcere will be responsible for distribution and commercialization in China, while Amgen will have a limited right to co-promote the products.
10/11/17 - AmpliPhi Biosciences to Participate in Two Upcoming Conferences
AmpliPhi Biosciences Corporation, a clinical-stage biotechnology company focused on the development of therapies for antibiotic-resistant infections using bacteriophage technology, today announced that management will present a company overview at two upcoming investor conferences:. AmpliPhi Biosciences Corporation is a clinical-stage...
10/11/17 - Amplyx Pharmaceuticals Highlights Phase 1 APX001 Data at IDWeek 2017
Release date- 10102017- SAN DIEGO- Amplyx Pharmaceuticals a company developing novel antimicrobial agents for life threatening fungal infections, today announced that it presented results from two Phase 1 studies of APX001, plus new nonclinical data highlighting its breadth of spectrum, at IDWeek 2017 held in San Diego, CA.. APX001 is a broad-spect
10/11/17 - ANSM grants authorisation for phase I/II clinical study for retinitis pigmentosa
The French National Agency for Medicines and Health Products Safety is set to launch a Phase I/II clinical trial for HORA-PDE6B, in the treatment of a retinitis pigmentosa...
10/11/17 - Antihistamine shown to improve function in MS patients
Researchers from the University of California, San Francisco, completed the clinical trial of the U.S. Food and Drug Administration- approved antihistamine clemastine fumarate on patients with MS. The study, published Tuesday in The Lancet, was the first to show a drug is capable of reliably restoring brain function damaged by a neurological diseas
10/11/17 - AntriaBio Appoints Nektar Therapeutics CFO to its Board of Directors
Release date- 10102017- LOUISVILLE, Colo.- AntriaBio, Inc., a biopharmaceutical company specializing in the development of innovative drug therapies for patients with metabolic diseases, announced today the appointment of Gil Labrucherie to its Board of Directors where he will serve as Chairman of the Audit Committee. Mr. Labrucherie is currently S
10/11/17 - Aravive Biologics Named as One of FierceBiotech's "Fierce 15" Biotech Companies of 2017
By a News Reporter-Staff News Editor at Biotech Week Aravive Biologics, Inc. announced that it has been named by FierceBiotech as one of 2017' s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry. "We are honored to be selected to the" Fierce 15 "class of 2017," said Ste
10/11/17 - ARM, EBE, EFPIA and EuropaBio Jointly Publish Series of Proposals to Streamline Requirements and Accelerate Approvals of Clinical Trials with New...
ARM, EBE, EFPIA and EuropaBio Jointly Publish Series of Proposals to Streamline Requirements and Accelerate Approvals of Clinical Trials with New Therapies Consisting of or Containing Genetically Modified Organisms in Europe. By a News Reporter-Staff News Editor at Biotech Week The Alliance for Regenerative Medicine, the European Biopharmaceutica
10/11/17 - Arsanis Presents Phase 1 and Preclinical Pharmacokinetic Data on Lead Product Candidate, ASN100, at IDWeek 2017
Release date- 10102017- WALTHAM, Mass. and VIENNA, Austria- Arsanis, Inc., a clinical-stage biopharmaceutical company focused on applying monoclonal antibody immunotherapies to address serious infectious diseases, today announced that the company presented pharmacokinetic data from a Phase 1 clinical trial in healthy volunteers and from a preclinic
10/11/17 - AstraZeneca - TAGRISSO granted Breakthrough Therapy Designation by US FDA for the 1stline treatment of patients with EGFR mutation positive non-small cell lung cancer
Release date- 10102017- AstraZeneca today announced that the US Food and Drug Administration has granted Breakthrough Therapy Designation for TAGRISSO for the 1st- line treatment of patients with metastatic epidermal growth factor receptor mutation-positive non-small cell lung cancer. Sean Bohen, Executive Vice President, Global Medicines...
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415